DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pharmaceutical Industry Business Confidence Report H1 2016" report to their offering.
The existing economic environment is stable for the pharmaceutical industry, and customer confidence levels will remain constant in H1 2016 (January 2016-June 2016). Companies are slightly optimistic about economic conditions in North America and Asia-Pacific due to positive momentum in the US manufacturing and production sectors, firm domestic demand, strong government expenditure in India, and robust private consumption and export growth in South Korea and Vietnam.
Over the next six months the industry will increase its expenditure towards new product development and IT infrastructure. Moreover, companies operating in Asia-Pacific forecast their budget allocation for pharmaceutical equipment to increase significantly in 2016, compared to 2015.
Key Findings
- In total, 43% of pharmaceutical industry business executives expect the global economy to be stable in H1 2016 (January 2016-June 2016). Furthermore, 33% of survey respondents anticipate a favorable or very favorable economic environment
- Overall, 83% of respondents who operate in Europe are optimistic over company growth prospects, while no executives anticipate a negative impact on the industry in the region
- Business executives operating in the Rest of the World region anticipate the highest increase in staff headcount growth over the next six months
- In H1 2016, the majority of business executives from North America are concerned about the performance of North American economies, the performance of the Eurozone, and cyber crime
- Survey results reveal that 41% of pharmaceutical industry respondents who operate in Asia-Pacific expect an increase of 1-5% in the budget for pharmaceutical equipment during 2016
Key Topics Covered:
1. Introduction
- Definitions
- Methodology and sample size
- Respondent profile
2. Economic State, growth prospects and customer confidence
- Existing economic environment
- Industry and company growth outlook
- Expected change in customer confidence
3. Supplier prices, staff headcount and sales performance
- Supplier prices expectations
- Anticipated change in staff head count and sales projections
- Anticipated change in spend on key activities
4. Business concerns and organizational priorities
- Level of concerns and expected impact
- Significance of potential business priorities
5. Procurement budget and expenditure outlook
- Purchase preferences for pharmaceutical equipment
- Frequency of investments towards various equipment categories
- Procurement of number of pieces of equipment
- Average expenditure per purchase
- Allocation of investment for equipment purchases
- Distribution of procurement budget between capital and operating expenditure
- Change in procurement budget expenditure
- Variation in pharmaceutical equipment budget from 2015 to 2016
- Leading suppliers across pharmaceutical equipment types
6. Appendix
Companies Mentioned
- Albany Molecular Research (AMRI)
- Baxalta
- GlaxoSmithKline (GSK)
- Johnson and Johnson (Pty) Ltd
- Mylan
- New York Center for Nanomedicine Research (NYCNMR)
- Shire
For more information visit http://www.researchandmarkets.com/research/843vw8/pharmaceutical
